NYSE · ARDT

Ardent Health Inc.

Healthcare · Medical - Care Facilities

$10.90▼ 2.24% ($0.25)at close

As of 4:00 PM ET

52-week

$7.71$15.48

Market cap

$1.56B

P/E

19.93

Volume

501.94K

Shares outstanding

143.35M

What the market price implies · Reverse DCF

To support a price of $10.90, this model requires Stage 1 FCFF to grow by -31.96%/yr over the next 5 years, compounded annually.

Historical FCFF grew by 10.95%/yr over the past 10 years. The required annual growth rate is 42.91 percentage points lower.

Selected forecast · Base scenario

10.95%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

-31.96%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$10.90

Estimated value / share

$141.37

Base scenario

This estimate is 1,196.93% above the price used.

USD · TTM ending 2026-06-30

FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.

Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.

Reported total debt includes capitalised leases (~51% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.

This estimate is at least 3× the price used. Review the assumptions behind the gap.

Stage 1 10.95% · Stage 2 6.02% · Discount rate 6.68%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 1:09 AM UTC · provider

Why this method?

FCFF is positive, but the year-to-year swings are too large for a direct CAGR. Normalize the cash-flow base first, then run DCF.

Is FCFF positive and has it been for 3+ consecutive years? 6 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 80.5%.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -16.35%Revenue (TTM): 3.34%FCF (TTM): 171.82%P/FCF: 25th pct

What changed

The stock fell 16.35% over the last year. Revenue grew 3.34% over the trailing twelve months. Operating margin moved from 9.87% to 7.54%. Free cash flow grew 171.82% over the trailing twelve months.

What the market seems to be pricing

The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 7.54%. A decisive move in revenue — currently up 3.34% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States.

CEODave Caspers

SectorHealthcare

IndustryMedical - Care Facilities

Employees22,350

IPO dateJul 18, 2024

https://www.ardenthealth.com

Market multiples

Forward P/E—

EV/EBITDA5.63

Enterprise value$2.8B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-1.4%

Gross margin29.96%▲14.9ppvs FY2024

Operating margin7.54%▼1.7ppvs FY2024

ROE6.01%▼3.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$13.50▲23.85%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est $0.24 · Revenue est $1.6B

View